Preprint Proteomic and metabolomic profiling of plasma uncovers immune responses in patients with Long COVID-19, 2024, Wei et al

Discussion in 'Long Covid research' started by forestglip, Dec 29, 2024.

  1. forestglip

    forestglip Senior Member (Voting Rights)

    Messages:
    1,208
    Proteomic and metabolomic profiling of plasma uncovers immune responses in patients with Long COVID-19

    Yulin Wei, Hongyan Gu, Jun Ma, Xiaojuan Mao, Bing Wang, Weiyan Wu, Shimin Yu, Jinyuan Wang, Huan Zhao, yanbin he

    [Preprint]

    Abstract
    Long COVID is an often-debilitating condition with severe, multisystem symptoms that can persist for weeks or months and increase the risk of various diseases. Currently, there is a lack of diagnostic tools for Long COVID in clinical practice. Therefore, this study utilizes plasma proteomics and metabolomics technologies to understand the molecular profile and pathophysiological mechanisms of Long COVID, providing clinical evidence for the development of potential biomarkers.

    This study included three age- and gender-matched cohorts: healthy controls (n=18), COVID-19 recovered patients (n=17), and Long COVID patients (n=15).

    The proteomics results revealed significant differences in proteins between Long COVID-19 patients and COVID-19 recovered patients, with dysregulation mainly focused on pathways such as coagulation, platelets, complement cascade reactions, GPCR cell signal transduction, and substance transport, which can participate in regulating immune responses, inflammation, and tissue vascular repair.

    Metabolomics results showed that Long COVID patients and COVID-19 recovered patients have similar metabolic disorders, mainly involving dysregulation in lipid metabolites and fatty acid metabolism, such as glycerophospholipids, sphingolipid metabolism, and arachidonic acid metabolism processes.

    In summary, our study results indicate significant protein dysregulation and metabolic abnormalities in the plasma of Long COVID patients, leading to coagulation dysfunction, impaired energy metabolism, and chronic immune dysregulation, which are more pronounced than in COVID-19 recovered patients.

    Link | PDF (Preprint) [Open Access]
     
    Lilas, Lindberg, Yann04 and 4 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,105
    Location:
    Aotearoa New Zealand
    I like the introduction. I like that there are matched groups of Long Covid, recovered and healthy controls. Group sizes are small though.

    The symptoms are a bit random. Numbers of the Long Covid group (total 15 people) with the following symptoms:
    Smell and taste dysfunction 4
    Fatigue 4
    Exertion dyspnea 5
    Muscular soreness 4
    Cough 3
    Loss of appetite 3
    Nausea 1

    As with so many of these studies, I doubt that the quality of the sample is good enough to warrant the subsequent application of technology and substantial effort. Can we really expect to find some clues when just looking at 15 people with that mixture of symptoms?

    I'm not sure if the problem is me - am I always expecting the researchers to look for the ME/CFS symptom constellation? Is it better to approach the Long Covid question without imposing pre-existing syndrome ideas? But, even so, I don't see how researchers can expect to find answers from a cohort with e.g. 4 people with smell or taste dysfunction who may not have other symptoms, when combined with 12 people without smell or taste dysfunction.
     
    EndME, alktipping, John Mac and 4 others like this.
  3. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    15,589
    Location:
    London, UK
    Complement and arachidonic acid metabolism mentioned again.
     
    alktipping, Lilas, Yann04 and 5 others like this.
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,105
    Location:
    Aotearoa New Zealand
    All that said (re my post), GNAI2 and TSP1 proteins do look to be different (both increased) in some of the LC cohort, compared to the other two cohorts, and so maybe are worth keeping in mind when looking at other 'omic studies.

    Screen Shot 2024-12-29 at 8.46.04 pm.png
     
    Last edited: Dec 29, 2024
  5. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,105
    Location:
    Aotearoa New Zealand
    On TSP1 (thrombospondin-1, THBS1)
    US: Annual ME/CFS Working Group Meetings from 2020. Stanford/OMF

     
    Last edited: Dec 29, 2024
    Lindberg, Yann04 and Peter Trewhitt like this.
  6. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    6,077
    Location:
    Aotearoa New Zealand
    And also sphingolipid metabolisim.
     
    alktipping, Hutan, Lindberg and 4 others like this.
  7. Sasha

    Sasha Senior Member (Voting Rights)

    Messages:
    4,347
    Location:
    UK
    I know zero about biology but I recognise this term and have the impression that someone was making a really big deal about it a few years ago. Ron Davis or someone in his wider group, maybe?
     
    alktipping, Yann04 and Peter Trewhitt like this.
  8. Hutan

    Hutan Moderator Staff Member

    Messages:
    30,105
    Location:
    Aotearoa New Zealand
    GNAI2
    googled snippets
     
  9. Murph

    Murph Senior Member (Voting Rights)

    Messages:
    159
    It may have been Naviaux 2017, Sphingolipid was among the strongest findings there :

    upload_2024-12-29_21-31-18.png

    This idea also brings Naviaux's thinking to mind, with his theories about failure to wrap up the cell danger response. Seems he has coined the term "salugenesis" to describe returning to health.

    Salugenesis is the automatic, evolutionarily conserved, ontogenetic sequence of molecular, cellular, organ system, and behavioral changes that is used by living systems to heal. It is a whole-body process that begins with mitochondria and the cell. The stages of salugenesis define a circle that is energy- and resource-consuming, genetically programmed, and environmentally responsive. Energy and metabolic resources are provided by mitochondrial and metabolic transformations that drive the cell danger response (CDR) and create the three phases of the healing cycle: Phase 1-Inflammation, Phase 2-Proliferation, and Phase 3-Differentiation.

    Each phase requires a different mitochondrial phenotype. Without different mitochondria there can be no healing. The rise and fall of extracellular ATP (eATP) signaling is a key driver of the mitochondrial and metabolic reprogramming required to progress through the healing cycle. Sphingolipid and cholesterol-enriched membrane lipid rafts act as rheostats for tuning cellular sensitivity to purinergic signaling. Abnormal persistence of any phase of the CDR inhibits the healing cycle,
     
    alktipping, Hutan, Trish and 2 others like this.
  10. Sasha

    Sasha Senior Member (Voting Rights)

    Messages:
    4,347
    Location:
    UK
    Thanks, @Murph, well-found! I'm pretty sure that was it. I don't know how his theory is thought of, at this point.
     
    alktipping, Trish and Peter Trewhitt like this.
  11. Jonathan Edwards

    Jonathan Edwards Senior Member (Voting Rights)

    Messages:
    15,589
    Location:
    London, UK
    Sphingomyelin is essential to coherent cell membrane structure.
    It might even be the writing on the (inside) wall!

    Choline, complement, lipid - there ought to be some way they make sense.

    The only thing I am a bit sceptical about is linking this to 'resolution of inflammation'. Ninety nine percent of our immune defence involves non-inflammatory mechanisms like silent complex clearance and induced apoptosis. Danger signals can operate without inflammation.
     

Share This Page